Literature DB >> 30580448

Dehydroepiandrosterone stimulates inflammation and impairs ovarian functions of polycystic ovary syndrome.

Yulin Li1, Qin Zheng1, Dan Sun1, Xinyuan Cui1, Siyi Chen1, Ahmmed Bulbul1, Shuai Liu1, Qiu Yan1.   

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common causes of infertility in child-bearing-age women. It is characterized by ovulation dysfunction, polycystic ovaries, and hyperandrogenism. Inflammation is likely to be a crucial contributor to the pathogenesis of PCOS. However, the association between the inflammatory cytokines and the development of PCOS has not been reported. To explore the relationship between the inflammatory cytokines and PCOS, alterations of serum proteins in dehydroepiandrosterone (DHEA)-induced PCOS rats were screened by protein array, and the concentration of IFN-γ was further measured by using enzyme-linked immunosorbent assay (ELISA). DHEA-induced PCOS rats had a decreased level of IFN-γ compared with the control rats, which was restored partly in flutamide (an androgen receptor antagonist)-treated rats. Moreover, the level of IFN-γ in serum of patients with PCOS was also lower than that in healthy women. Using the ovarian granulosa cells (KGN), we demonstrated that DHEA downregulated the expression and secretion of IFN-γ in dose- and time-dependent manners, which could be restored to some extent by treating with flutamide. Furthermore, flutamide ameliorated the inhibitory effect on cell proliferation and promotive effect on cell apoptosis by DHEA. The results also revealed that IFN-γ promoted the proliferation but inhibited the apoptosis of KGN cells, which was suppressed by DHEA via activating the downstream PI3K/AKT signaling pathway. Taken together, these results showed that DHEA inhibited the proliferation and promoted the apoptosis of ovarian granulosa cells through downregulating the expression of IFN-γ which could be restored by flutamide, and IFN-γ may serve as a potential inflammatory biomarker for PCOS detection.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  DHEA; IFN-γ; PCOS; ovarian granulosa cells

Year:  2018        PMID: 30580448     DOI: 10.1002/jcp.27501

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  16 in total

1.  Role of CPXM1 in Impaired Glucose Metabolism and Ovarian Dysfunction in Polycystic Ovary Syndrome.

Authors:  Sadaf Pervaz; Amin Ullah; Enoch Appiah Adu-Gyamfi; Jones Lamptey; Sanjay Kumar Sah; Mei-Jiao Wang; Ying-Xiong Wang
Journal:  Reprod Sci       Date:  2022-06-13       Impact factor: 3.060

2.  MiR-383-5p promotes apoptosis of ovarian granulosa cells by targeting CIRP through the PI3K/AKT signaling pathway.

Authors:  Yunying Li; Xiaohua Wu; Suibing Miao; Qinying Cao
Journal:  Arch Gynecol Obstet       Date:  2022-02-28       Impact factor: 2.493

3.  Elevated ovarian pentraxin 3 in polycystic ovary syndrome.

Authors:  Jiexue Pan; Chengliang Zhou; Zhiyang Zhou; Zuwei Yang; Tiantian Dai; Hefeng Huang; Li Jin
Journal:  J Assist Reprod Genet       Date:  2021-02-16       Impact factor: 3.412

4.  Ferroptosis inhibitor ferrostatin‑1 alleviates homocysteine‑induced ovarian granulosa cell injury by regulating TET activity and DNA methylation.

Authors:  Qing Shi; Rui Liu; Li Chen
Journal:  Mol Med Rep       Date:  2022-02-16       Impact factor: 2.952

5.  DHEA and polycystic ovarian syndrome: Meta-analysis of case-control studies.

Authors:  Jiby Jolly Benjamin; MaheshKumar K; Teena Koshy; Maruthy K N; Padmavathi R
Journal:  PLoS One       Date:  2021-12-21       Impact factor: 3.240

6.  The PNA mouse may be the best animal model of polycystic ovary syndrome.

Authors:  Jingyi Ren; Guangqing Tan; Xinyi Ren; Weiyu Lu; Qiling Peng; Jing Tang; Yingxiong Wang; Biao Xie; Meijiao Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-08       Impact factor: 6.055

7.  Korean Red Ginseng alleviates dehydroepiandrosterone-induced polycystic ovarian syndrome in rats via its antiinflammatory and antioxidant activities.

Authors:  Jong Hee Choi; Minhee Jang; Eun-Jeong Kim; Min Jung Lee; Kyoung Sun Park; Seung-Hyun Kim; Jun-Gyo In; Yi-Seong Kwak; Dae-Hun Park; Seung-Sik Cho; Seung-Yeol Nah; Ik-Hyun Cho; Chun-Sik Bae
Journal:  J Ginseng Res       Date:  2019-08-26       Impact factor: 6.060

8.  Mesenchymal stem cell therapy ameliorates metabolic dysfunction and restores fertility in a PCOS mouse model through interleukin-10.

Authors:  Rishi Man Chugh; Hang-Soo Park; Abdeljabar El Andaloussi; Amro Elsharoud; Sahar Esfandyari; Mara Ulin; Lale Bakir; Alshimaa Aboalsoud; Mohamed Ali; Dalia Ashour; Prosper Igboeli; Nahed Ismail; Jan McAllister; Ayman Al-Hendy
Journal:  Stem Cell Res Ther       Date:  2021-07-07       Impact factor: 6.832

Review 9.  Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing.

Authors:  Hosna Mohammad Sadeghi; Ida Adeli; Daniela Calina; Anca Oana Docea; Taraneh Mousavi; Marzieh Daniali; Shekoufeh Nikfar; Aristidis Tsatsakis; Mohammad Abdollahi
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

Review 10.  Polycystic Ovarian Syndrome: A Complex Disease with a Genetics Approach.

Authors:  Himani Nautiyal; Syed Sarim Imam; Sultan Alshehri; Mohammed M Ghoneim; Muhammad Afzal; Sami I Alzarea; Emine Güven; Fahad A Al-Abbasi; Imran Kazmi
Journal:  Biomedicines       Date:  2022-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.